Extracorporeal photochemotherapy is an effective treatment for cutaneous T cell lymphoma but its mode of action is uncertain. The reduction in viability of patients' photoirradiated buffy coat lymphocytes was correlated with a 35% increase in DNA single-strand breaks and marked decreases in cellular ATP and NAD levels (to 58 and 34% of control, respectively) immediately after photoirradiation. Complementary in vitro studies were conducted with normal human peripheral blood lymphocytes using a Therakos ultraviolet A (UVA) light box. UVA light was cytotoxic on its own but was potentiated by 8-methoxypsoralen. 3-aminobenzamide, a poly (ADP-ribose) synthetase inhibitor, mitigated the cytotoxic effect of ultraviolet A light in the presence of 8-methoxypsoralen in lymphocytes and reduced the amount of nucleotide depletion they caused. 10 J/cm2 of UVA light in the presence of 300 ng/ml 8-methoxypsoralen increased the poly (ADP-ribose) synthetase activity of peripheral blood lymphocytes. Exposing lymphocytes to deoxycoformycin and deoxyadenosine was found to induce biochemical and physical effects similar to those of photochemotherapy. In summary, we have shown that the lymphocytotoxic effect of extracorporeal photochemotherapy for cutaneous T cell lymphoma is apparently mediated by DNA damage, subsequent poly (ADP-ribosyl)ation and adenine nucleotide depletion. It is not known how the DNA damage and resultant biochemical effects relate to the possible immunological mechanism of extracorporeal photochemotherapy; however, it is possible that its effects can be mimicked by other DNA-damaging agents. (J. Clin.
type (1) . The diseases encompassed include Sezary syndrome, mycosis fungoides, and various adult T cell leukemias. There are up to 10 ,000 new cases per year in the USA; it is more common in males and usually diagnosed after the age of 40. It typically remains localized to the skin for a time, then evolves into a nonepidermotropic stage in which there is dissemination and involvement of other organ systems. Extracutaneous spread is associated with refractoriness to treatment and a poor prognosis.
Therapy for disseminated CTCL includes systemic chemotherapy, leukapheresis, and the use of monoclonal antibodies directed against the malignant lymphocyte phenotype. Oral 8-methoxypsoralen (8-MOP) photochemotherapy is effective in early stage skin-localized CTCL (2, 3) . It produces few side effects, does not cross-react with other treatments, and results in relatively long-lived remissions. Its effects are limited to tissues exposed to ultraviolet A (UVA) because of the short half-life of the photoactive form of the drug.
In 1987, Edelson (4) described 37 patients with CTCL treated with "extracorporeal photochemotherapy" (ECPC). In this technique, following an oral dose of 8-MOP, patients were leukapheresed and their buffy coat lymphocytes extracorporeally exposed to UVA light for 3 h, and then reinfused into the donor patient. 73% of all patients responded with a mean of 64% decrease in cutaneous involvement (skin score). Their median survival is now in excess of 4 yr (less than 50% of the 37 patients are now dead), greater than that for historical con- trols.
Psoralens are bifunctional photoreagents that form covalent bonds with pyrimidine bases of nucleic acids (5) . They consist of a furan ring and a coumarin. Their planar structure enables them to intercalate into double-stranded nucleic acid and undergo covalent addition at either the furan or coumarin end. Photoaddition occurs with long wavelength UVA light (320-400 nm). The monoadducts and covalent interstrand crosslinks (diadducts) it forms are chemically stable. 8-MOP is absorbed orally reaching peak levels 1-4 h later and is almost entirely excreted by 24 h. It has been reported that to exert a therapeutic effect the plasma 8-MOP level must exceed 50 ng/ml during the period of UVA irradiation (4) .
The mechanism of action of ECPC in CTCL is not well understood. There is evidence that when the damaged lymphocytes are returned to the patient they incite an immune reaction (4) . In In vitro experiments on the mechanisms of 8-MOP and UVA photochemotherapy-induced cytotoxicity in PBL. Sham photochemotherapy treatment experiments were conducted with peripheral blood lymphocytes from normal blood bank volunteers. These experiments enabled variation of the intensity of UVA light, the concentration of 8-MOP, and the interaction between 8-MOP and UVA light to be studied in an attempt to elucidate the mechanism of lymphocytotoxicity.
Viability. Control experiments revealed that 8-MOP alone (without UV irradiation) was not toxic to PBL: 10-300 ng/ml did not affect corrected viability after 72 h incubation at 37°C. The effect on lymphocyte viability of a wide range of doses of UVA light (0.1-10 J/cm2) was studied: the results for 1 and 2 J/cm2 (the dose given to patients) are shown in Fig. 2 A. The addition of 8-MOP clearly potentiated the cytotoxicity caused by UVA light; however, the potentiating effect was dependent on the dose of UVA light. At doses of 3 J/cm2 and above there was minimal potentiation (data not shown), while at 1-2 J/cm2 the potentiation was marked. 8-MOP concentrations higher than 50 ng/ml did not further increase cytotoxicity in PBL (data not shown).
Many cytotoxic agents that are thought to mediate their cytotoxic effect via poly (ADP-ribosyl)ation have their cytotoxicity reduced (or completely eliminated) by the addition of specific poly (ADP-ribose) synthetase inhibitors. The addition of 3-aminobenzamide (ABA) (2 mM), a dose sufficient to inhibit poly (ADP-ribose) synthetase but which did not affect lymphocyte viability, decreased the cytotoxic effect of exposing PBL to 2 J/cm2 UVA and 300 ng/ml 8-MOP. This dose of 8-MOP was chosen to maintain an excess of the drug. The viability of the 3-ABA and UVA/8-MOP treated cells (99% at 48 h) was significantly different from the control UVA/8-MOP group (61%, P < 0.001) (Fig. 2 B) . The protective effect occurred whether the 3-ABA was added before or after irradiation; this excludes the possibility that 3-ABA mitigated the cytotoxic effect merely by decreasing the dose of UVA received by the PBL.
DNA damage. The DNA damage for a range (1-5 J/cm2) of UVA light doses was studied 2 h after irradiation (Fig. 3) . The DNA-damaging effects of UVA light on PBL was potentiated by the addition of 8-MOP. However, the extent of this potentiating effect was dependent on the dose of UVA light and the timing ofthe assay. Edelson (4) reported that the dose of UVA light delivered to his patients' buffy coat lymphocytes was 1-2 J/cm2; we have shown that in vitro this was the dose where 8-MOP maximally potentiated the DNA damage caused by UVA light. In the sham experiments this dose induced a level of DNA strand breaks similar in extent to those in the patients' samples. At 1.5 J/cm2 8-MOP increased the number of DNA SSBs by more than twofold. There was far less damage at 24 h (< 15% increase in DNA SSBs) than there was at 2 h, presumably reflecting DNA repair (data not shown). 5 J/cm2 of UVA light caused only slightly more DNA SSBs than 2 J/cm2: this suggests a ceiling effect.
Nucleotide content. Exposures of PBL to 1-40 J/cm2 UVA light alone caused a nonlinear dose-dependent depletion of NAD and ATP 2 h after exposure (Fig. 4 A) . Between 1 and 10 J/cm2 there was a steep increase in nucleotide depletion with further depletion only occurring at very high doses of UVA light. 8-MOP potentiated the NAD-depleting effects of UVA light alone. A 1 J/cm2 UVA light exposure depleted PBL of 11% of their NAD content; adding 8-MOP (300 ng/ml) increased the total NAD depletion to 34% (representative experiment, mean of five observations). At higher UVA doses (2-10 J/cm2) this potentiating effect was not apparent (data not shown). The addition of 8-MOP to 1-2 J/cm2 UVA light did not further increase ATP depletion.
2 mM 3-ABA also mitigated the nucleotide depletion caused by 10 J/cm2 of UVA light and continuous exposure to 300 ng/ml 8-MOP (Fig. 4 B) . This dose of UVA light was chosen because it caused substantial NAD and ATP depletion; therefore, the mitigating effect of 3-ABA could be clearly demonstrated.
Poly (ADP-ribose) synthetase activity. PBL were exposed to 10 J/cm2 UVA light in the presence of 300 ng/ml 8-MOP; at 2 h poly (ADP-ribose) synthetase activity rose to 160% ofcontrol (three experiments of three to five samples). Significant elevations in enzyme activity were not demonstrable with lower doses of UVA light. 8-MOP alone (300 ng/ml) did not affect J/cm2 of UVA light was the dose delivered to them. It is also noteworthy that, even with lethal doses (2 J/cm2) of UVA light and 8-MOP, the DNA damage present at 2 h was much greater than that at 24 h after exposure. It appears that this early DNA damage caused a series of biochemical events that irreversibly damaged the cell and that subsequent DNA repair did not affect this.
This UVA/8-MOP-associated DNA damage is associated with adenine nucleotide depletion. This study also presents some evidence that stimulation of poly (ADP-ribosyl)ation and consequent nucleotide depletion are involved in the lymphocytotoxic effect of photoactivated psoralens. Photoirradiation in the presence of 8-MOP caused significantly elevated levels of poly (ADP-ribose) synthetase activity. However, elevated enzyme activity levels were only found at high doses (10 J/cm2) of UVA light. The failure to demonstrate elevated enzyme levels at 1-2 J/cm2 may be due to the insensitivity of the assay or may reflect the transient nature of the rise in enzyme activity. The poly (ADP-ribose) synthetase inhibitor, 3-ABA, mitigated the cytotoxicity of photoirradiation and reduced the nucleotide depletion it caused. These three pieces of data are regarded as important evidence for the involvement of poly (ADP-ribosyl)ation (1 1). Poly (ADP-ribosyl)ation accounts for the majority of NAD turnover in the lymphocyte: it would appear to be the most likely cause for the changes in NAD content that we have demonstrated. A degree of caution is required in the interpretation of the correlations between clinical response and various biochemical parameters. The number of patients was small and although response correlated with ATP depletion it did not correlate with other parameters of cell kill.
In vitro studies in which normal PBL were treated with dCF and dAdo showed many similarities with the effects of ECPC on lymphocytes of patients with CTCL. The rate of cell kill, DNA strand breakage and extent of NAD and ATP depletion were all similar. Carson (12) originally demonstrated that dAdo and dCF caused DNA strand breaks, depleted cells of NAD and ATP, and increased levels of poly (ADP-ribose) synthesis. He found that nicotinamide and 3-ABA protected against these changes. We have shown that photoirradiation is also apparently associated with stimulation of poly (ADP-ribosyl)ation. Although 3-ABA can prevent adenine nucleotide depletion, it appears the biochemical damage to cells is irreversible ( 13) .
It appears that photochemotherapy may have an immunologic mechanism of action. First, the superiority of ECPC to simple leukapheresis is evidence that reinfusion of the damaged (dying) cells is important. Delayed death of the reinfused, damaged lymphocytes may be important; there may need to be sufficient time for them to excite an immunological response in patients with CTCL. Second, immunocompetent patients respond better than those with impaired immunity (4). Third, there is a reduction in malignant cells in the skin (cells that have not been exposed to ECPC) that suggests they have been eradicated by a mechanism of host origin (4). It has been postulated that the reinfused damaged cells induce the proliferation of lymphocytes bearing antiidiotypic receptors that recognize the malignant clone.
We have shown the increased expression of various activation markers by lymphocytes from CTCL patients soon after treatment with ECPC (14) . The UVA/8-MOP-induced changes in the reinfused peripheral blood lymphocytes may induce antigenic changes in their cell surface membranes, which might be responsible for this immune stimulation.
The practical implications of the findings in this report are that the extracorporeal treatment of patients' buffy coat with a combination of dAdo plus dCF (or other lymphocytotoxic agents) may achieve similar effects to ECPC. This is of some importance when the potential wider application of ECPC to autoimmune disease is considered. Replacement of ECPC by exposure of the buffy coat specimens to conventional DNAdamaging agents would be far more convenient. To test this hypothesis further we are conducting studies comparing infusions of photochemotherapy-affected and cytotoxic drug-damaged splenocytes as treatment of an animal autoimmune model of disease.
